Case Report: Composite Angioimmunoblastic T-Cell Lymphoma and Epstein-Barr Virus-Positive B-Cell Lymphoproliferative Disorder as Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders

Seiji Kakiuchi¹,²*, Kimikazu Yakushijin², Ikumi Takagi¹, Junpei Rikitake¹,², Hiroaki Akiyama¹, Hiroyuki Matsuba¹, Yoshitake Hayashi³, Kazuyoshi Kajimoto⁴ and Nobuko Iwata¹

¹ Department of Hematology, Yodogawa Christian Hospital, Osaka, Japan, ² Division of Medical Oncology and Hematology, Kobe University Graduate School of Medicine, Kobe, Japan, ³ Division of Molecular Medicine & Medical Genetics, Department of Pathology, Kobe Graduate School of Medicine, Kobe, Japan, ⁴ Department of Pathology, Hyogo Cancer Center, Akashi, Japan

Immunosuppressants are widely used to treat patients with rheumatoid arthritis (RA), and their adverse effects have been known to cause other iatrogenic immunodeficiency-associated lymphoproliferative disorders (OIIA-LPDs). We report a patient with RA who had been treated with methotrexate (MTX) and tacrolimus (TAC) and who developed whole body lymphadenopathy. We simultaneously confirmed angioimmunoblastic T-cell lymphoma (AITL) through a right cervical lymph node biopsy and Epstein-Barr virus-positive B-cell lymphoproliferative disorder (EBV-positive B-LPD) through a bone marrow examination. After cessation of immunosuppressant therapy, both LPDs completely disappeared. Patients with AITL are occasionally reported to develop B-cell lymphoma through reactivation of the EBV, which leads to clonal expansion in the microenvironment. Immunohistochemistry results revealed that both LPD components were positive for EBV-encoded RNA. Moreover, in this patient, the plasma EBV DNA level was found to be high; therefore, EBV infection was a probable etiology. Synchronous coexistence of AITL and B-LPD as an OIIA-LPD has rarely been reported. This case report is the first to discuss the disappearance of both LPDs on withdrawal of immunosuppressants only. AITL occasionally accompany B-LPD; however, this composite lymphoma comprised AITL and B-LPD, and OIIA-LPDs should not be overlooked.

Keywords: composite lymphoma, Epstein-Barr virus reactivation, methotrexate, angioimmunoblastic T-cell lymphoma (AITL), clonal expansion

INTRODUCTION

According to the World Health Organization classification of tumors of hemopoietic and lymphoid tissues, other iatrogenic immunodeficiency-associated lymphoproliferative disorder (OIIA-LPD) is categorized as an immunodeficiency-related lymphoproliferative disorder. It is associated with anti-rheumatoid arthritis drugs including methotrexate (MTX), tacrolimus (TAC),...
| Case (References) | Age/Sex subtype | Disease site | Biopsy site | MTX duration (year) | EBER in tumor cell | EBER in background | EBV-DNA copy (/10^6 cells) | First line Management | Second line Management | SR | Response | Recurrence or Progression | Outcome (month) |
|------------------|----------------|--------------|-------------|--------------------|-------------------|--------------------|----------------------|----------------------|----------------------|----|----------|--------------------------|----------------|
| Case 1 (6)       | 66/F           | CD80+ PC T-LPD | Skin        | Skin               | NA                | +                  | NA                   | Off MTX              | –                   | +  | CR        | No                       | Alive          |
| Case 2 (7)       | 75/F           | CD8+ T-LPD    | Liver, spleen, LNs | LN                | 7                 | +                  | NA                   | 7,400                | Off MTX              | –  | +                    | CR           | No 2 | Alive          |
| Case 3 (8)       | 71/F           | AITL-like     | LNs         | LN                 | 20                | –                  | +                    | NA                   | Off MTX              | –  | +                    | CR           | No 7 | NA             |
| Case 4 (9)       | 68/M           | AITL-like     | LN          | NA                 | –                 | +                  | NA                   | Off MTX              | –                   | +  | CR        | No                       | Alive          |
| Case 5 (10)      | 67/M           | AITL-like     | LN          | LN                 | 16                | –                  | +                    | NA                   | Off MTX              | –  | +                    | CR           | Yes  | Alive         |
| Case 6 (12)      | 60/M           | AITL         | LNs         | LN                 | 0.6               | –                  | NA                   | Off MTX              | Chemotherapy         | –  | +                    | PR           | Yes  | Alive         |
| Case 7 (12)      | 66/F           | AITL         | LN          | LN                 | 0.4               | –                  | +                    | 290                  | Off MTX              | Off MTX       | +        | CR         | Yes (DLBCL)              | Alive 18       |
| Case 8 (12)      | 48/F           | CD8+ T-LPD    | Lungs, LNs, kidney, liver, spleen | LN | 11.1 | – | + | NA | Off MTX | – | + | PR | No | Alive  |
| Case 9 (11)      | 78/M           | PTCL-NOS      | LNs         | LN                 | 5.5               | +                  | NA                   | NA about MTX         | –                   | NA | CR        | No                       | Alive 1         |
| Case 10 (12)     | 59/F           | T-LGL         | BM, LN      | NA                 | NA                | –                  | –                    | NA                   | Chemotherapy         | –  | +                    | CR           | No 12 | Alive         |
| Case 11 (12)     | 69/F           | ALK-ALCL      | LN          | LN                 | NA                | –                  | –                    | NA                   | Chemotherapy         | –  | No cessation | NA                       | Dead 2         |
| Case 12 (12)     | 61/F           | T-LGL         | BM, LN      | NA                 | NA                | –                  | –                    | NA                   | Off MTX              | –  | +                    | CR           | No 6   | Alive         |
| Case 13 (12)     | 70/M           | AITL to T-ML, nos | LN | NA | AITL- | + | NA | Off MTX | CHOP | + | CR         | Yes                      | Alive 65        |
| Case 14 (12)     | 31/M           | SPTCL         | Subcutis    | Subcutis           | NA                | –                  | –                    | NA                   | Off MTX              | –  | +                    | CR           | No 24 | Alive         |
| Case (References) | Age/Sex subtype | Disease site | Biopsy site | MTX duration (year) | EBER in tumor cell | EBER in background | EBV-DNA copy (10^6 cells) | First line Management | Second line Management | SR | Response | Recurrence or Progression | Outcome (month) |
|-------------------|----------------|--------------|-------------|---------------------|-------------------|---------------------|------------------------|----------------------|-----------------------|----|----------|------------------------|-----------------|
| Case 15 (4) | 75/M | T-pleomorphic | NA | NA | 24 | NA | NA | Off MTX | – | NA | NA → PD | NA | DOD |
| Case 16 (4) | 58/M | T-LGL | NA | NA | 6 | NA | NA | Off MTX | – | + | CR | No | Alive |
| Case 17 (13) | 77/M | PTCL-NOS | LNs | LN | 22 | - | NA | Off MTX | CHOP | - | PD | Yes | Died for infection 41 |
| Case 18 (14) | 60/M | SPTCL | Subcutis, abdominal cavity | NA | + | NA | 2,000 | Off MTX | – | + | CR | No | Alive |
| Case 19 (15) | 44/F | PTCL-NOS | Nasal sputum, maxillary sinus, lungs, LNs | LN | 5 | + | + | 420 | Off MTX | – | + | CR | No | Alive |
| Case 20 (16) | 66/F | CD30+ T-LPD | Lips | Lower lip | >5 | + | NA | Off MTX | – | + | CR | No | Alive |
| Case 21 (17) | 74/F | AITL | LNs | LN | 8 | - | + | NA | Off MTX | – | + | PR | No | Died for DIC 0 |
| Case 22 (17) | 81/M | AITL | LNs | LN | NA | - | + | NA | Off MTX | – | + | CR | No | Alive |
| Case 23 (17) | 78/M | AITL | LNs | LN | 5.5 | - | + | NA | Off MTX | – | + | CR | No | Alive |
| Case 24 (17) | 69/M | AITL | LNs | LN | 1 | - | + | NA | Off MTX | – | + | PR | No | Alive with disease 4 |
| Case 25 (17) | 75/F | AITL | LNs | LN | 0.5 | - | + | NA | Off MTX | NA | + | CR → PD | Yes | DOD 49 |
| Case 26 (17) | 67/M | AITL | LNs, PB, subcutis | LN | 6 | - | + | NA | Off MTX | – | + | CR | No | Alive |
| Case 27 (17) | 66/F | AITL | LNs, BM | LN | 2.5 | - | + | NA | CHOP | Off MTX | NA | + | CR → PD | Yes (DLBCL) | DOD 93 |

(Continued)
TABLE 1 | Continued

| Case (References) | Age/Sex | subtype | Disease site | Biopsy site | MTX duration (year) | EBER in tumor cell | EBER in background | EBV-DNA copy (/10^6 cells) | First line Management | Second line Management | SR | Response | Recurrence or Progression | Outcome (month) |
|-------------------|---------|---------|--------------|-------------|---------------------|-------------------|-------------------|----------------------|----------------------|----------------------|----|----------|---------------------------|-----------------|
| Case 28 (17)      | 72/F    | AITL, EBV+ B-LPD | LN, skin, spleen, skin | LN, skin | NA                  | -                 | +                 | NA                   | Off MTX              | -                    | CR | No       | Alive                      | 6               |
| Case 29 (17)      | 57/M    | AITL    | LN           | LN          | 5                   | -                 | -                 | NA                   | Off MTX              | -                    | CR | No       | Alive                      | 45              |
| Case 30 (17)      | 75/M    | AITL    | LN           | LN          | 2.4                 | -                 | +                 | NA                   | Off MTX, Sobuzoxane + ETO | -                    | CR | No       | Alive                      | 45              |
| Case 31 (17)      | 69/M    | AITL with LN, EBV+HRS | LN | 21           | -                 | +                 | NA                   | Off MTX              | -                    | CR | No       | Alive                      | 65              |
| Case 32 (17)      | 67/F    | AITL    | LN, PB       | LN          | 4.5                 | -                 | +                 | NA                   | CHOP                 | -                    | CR | No       | Alive                      | 68              |
| Case 33 (17)      | 79/M    | AITL with LN, EBV+HRS | LN | 2.5           | -                 | +                 | NA                   | Off MTX, Sobuzoxane + ETO | -                    | CR | No       | Alive                      | 65              |
| Case 34 (17)      | 79/M    | AITL    | LN           | LN          | 15.5                | -                 | +                 | NA                   | COP, THP-COP         | -                    | CR | No            cessation | Alive                      | 2               |
| Case 35 (17)      | 85/M    | AITL with LN, EBV+HRS | LN | 0.9           | -                 | +                 | NA                   | Off MTX              | -                    | CR | No       | Alive                      | 9               |
| Case 36 (17)      | 70/M    | AITL    | LN, Extranalodal >1 | LN          | 18.4                | -                 | +                 | NA                   | Off MTX              | -                    | CR | No       | Alive                      | 1               |
| Case 37 (17)      | 76/M    | AITL    | LN           | LN          | 1.8                 | -                 | +                 | NA                   | Off MTX              | -                    | CR | No       | Alive                      | 68              |
| Case 38 (17)      | 67/F    | AITL    | LN           | LN          | 0.5                 | -                 | -                 | NA                   | CHOP                 | -                    | CR | No            cessation | Alive                      | 66              |
| Case 39 (17)      | 62/M    | AITL    | LN, liver, spleen, adrenal gland | LN | 3                   | -                 | +                 | NA                   | Off MTX, Sobuzoxane + ETO | -                    | CR | No       | Yes                        | 14              |
| Case 40 (17)      | 63/F    | PTCL-NOS of Tfh | LN | 10           | -                 | +                 | NA                   | Off MTX              | -                    | CR | PD       | No                         | 25              |

(Continued)
| Case (References) | Age/Sex subtype | Disease site | Biopsy site | MTX duration (year) | EBER in tumor cell | EBER in background | EBV-DNA copy (10^6 cells) | First line Management | Second line Management | Response | Recurrence or Progression | Outcome (month) |
|-------------------|----------------|--------------|-------------|---------------------|-------------------|-------------------|---------------------|----------------------|----------------------|----------|--------------------------|-----------------|
| Case 41 (17)      | 76/F PTCL-NOS  | LN           | LN          | 1.3                 | –                 | –                 | NA                  | Off MTX              | –                    | CR       | No                       | Alive           |
| Case 42 (17)      | 64/M PTCL-NOS  | LN, ST       | ST          | 7.7                 | –                 | –                 | NA                  | Off MTX              | NA                   | CR→PD    | Yes                      | DOD             |
| Case 43 (17)      | 80/F PTCL-NOS  | LN, oral mucosa | Oral mucosa | 9.3                 | –                 | –                 | NA                  | Off MTX              | –                    | CR       | No                       | Alive           |
| Case 44 (17)      | 63/M PTCL-NOS with EBV+ HRS | LN | LN | 2.3 | – | – | NA | Off MTX | – | CR | No | 12 | Alive |
| Case 45 (17)      | 56/F CutaneousSkin PTCL-NOS | Skin | Skin | 4.3 | – | – | NA | CHOP Off MTX | – | CR | No | 21 | Alive |
| Case 46 (17)      | 72/F CD8+ Cytotoxic T-LPD | LN, pleural E, pericardial LN | LN | 3 | – | – | NA | Off MTX | – | CR | No | 20 | Alive |
| Case 47 (17)      | 57/F CD8+ Cytotoxic T-LPD | LN, BM, spleen | BM | 0.5 | – | – | NA | Off MTX | – | CR | No | 66 | Died for ASO and RB |
| Case 48 (17)      | 65/F CD8+ Cytotoxic T-LPD | LN, liver, kidney | Liver | 3 | – | – | NA | Off MTX | – | CR | No | 80 | Alive |
| Case 49 (17)      | 74/F ATL lymphoma type | LN | LN | 5 | – | – | NA | Off MTX | No | CR→PD | Yes | 13 | DOD |
| Present Case      | 73/M AITL EBV-positive B-cell LPD | LN, BM | LN | 17.8 | – | – | 1,700 | Off MTX | – | CR | No | 14 | Alive |

**Note:** EITL, angioimmunoblastic T-cell lymphoma; ALCL, anaplastic large cell lymphoma; AITL, adult T-cell lymphoma; BM, bone marrow; CR, complete response; DLBCL, diffuse large B-cell lymphoma; DOD, died of disease; E, effusion; EBV, Epstein-Barr virus; EBER, EBV-encoded small RNA; F, female; HRS, Hodgkin-Reed-Sternberg; LGL, large granular lymphocytic leukemia; LN, lymph node; LPD, lymphoproliferative disorder; M, male; MO, months; MTX, methotrexate; NA, not available; NOS, not otherwise specified; NR, no response; PC, primary cutaneous; PD, progressive disease; PR, partial response; PS, performance status; PTCL, peripheral T-cell lymphoma; RB, rectal bleeding; SR, spontaneous regression; ST, subcutaneous tissue; TH, follicular helper T cell; y, year.
and biological disease-modifying anti-rheumatic medication such as anti-TNFα drugs (1). B-cell lymphoma and Hodgkin lymphoma comprise most OIIA-LPDs, whereas T-cell lymphoma or natural killer (NK)/T-cell lymphoma comprise between 4 and 8% only (1–5). To date, only 50 patients (men, n = 26; women, n = 24) with MTX-associated T-LPDs (MTX T-LPDs) have been reported, including our patient, as detailed in Table 1 (2, 4, 6–18). Of these, 49 patients were treated for rheumatoid arthritis (RA) and one patient was treated for polymyalgia rheumatica. Data concerning the duration of MTX usage was available for 38 patients, and the median duration was 5 years (range, 0.4–24 years). Treatment for 38 patients initially involved the withdrawal of MTX only and, of these, 35 patients improved post-MTX cessation [complete response (CR), n = 31; partial response (PR), n = 4]. Chemotherapy was the initial treatment for 12 patients and response data was recorded for 10 patients [CR, n = 9; progressive disease (PD), n = 1]. Finally, data of 48 patients were available comprising 35 patients with a CR, four patients with a PR, and nine patients with PD. In total, 10 of 48 patients relapsed or progressed after initial treatment.

We encountered a 73-year-old male with a long medication history of MTX and TAC administration for the treatment of RA, who developed composite lymphomas consisting of angioimmunoblastic T-cell lymphoma (AITL) and Epstein-Barr virus-positive B-cell lymphoproliferative disorder (EBV-positive B-LPD). Considering the possibility of OIIA-LPD, we discontinued immunosuppressant therapy and undertook careful observation. Immunohistochemical test results indicated composite lymphomas, and both tumors were EBV-encoded RNA (EBER)-positive. In addition, his plasma level of EBV DNA copies was also high. He achieved CR only after immunosuppressant withdrawal. Therefore, composite lymphomas can be considered MTX-associated LPDs with different lineages and, here, we report one such type as a first case.

**CASE PRESENTATION**

A 73-year-old man with a 20-year history of RA and a medication history of MTX (duration, 17.8 years), TAC (duration, 10.2 years), and prednisolone (PSL) was admitted to our hospital with a 4-day history of high fever and fatigue. On arrival, his vital signs were normal, except for his heart rate (113 beats/min) and body temperature (40.1°C). On physical examination, we observed right cervical lymphadenopathy. His blood test results are described in Table 2. His soluble IL-2 receptor (sIL-2R) level was markedly elevated (11,200 IU/mL; normal range, 145–519 IU/mL). A whole body computed tomography (CT) scan revealed bilateral cervical, subclavian, axilla, inguinal, mediastinal, portal, periaortic, and pelvic lymph node swelling. Given his medication history of immunosuppressant therapy, we assumed the possibility of an OIIA-LPD and consequently discontinued MTX and TAC. We continued PSL only and started intravenous antibiotics, and his elevated body temperature was soon resolved. On day 2, a bone marrow examination was conducted, and a cervical lymph node biopsy was performed on day 7.

Histopathological examination of the bone marrow biopsy revealed scattered infiltration of large atypical lymphocytes (Figures 1A,B). These cells were positive for CD20, CD25,
and MUM1, and negative for CD3 (Figure 1C). EBER-positive lymphocytes were detected using in situ hybridization background staining (Figure 1D). However, histological examination of the lymph nodes showed an effaced structure with a marked increase in small-to-medium-sized atypical mononuclear cells with irregular nuclei and clear cytoplasm in a background of arborizing endothelial venules (Figures 2A,B). Immunostaining showed these atypical cells were positive for CD3 and CD4, and large immunoblastic lymphocytes scattered among the neoplastic cells were positive for CD20 (Figure 2C). No Reed-Sternberg-like cells were observed. In addition, the neoplastic cells were positive for BCL6 and CD10, suggestive of the follicular T-helper cell phenotype. Podoplanin immunostaining, a highly effective marker of follicular dendritic cells, showed an expanded follicular dendritic cell meshwork, although it was negative for CD21 (Figure 2D) (19, 20). PD-1-positive lymphocytes were EBER-negative, while CD20-positive background cells were EBER-positive (Figures 2E,F).

Diagnoses of AITL from cervical lymph nodes and of EBV-positive polymorphic B-LPD from bone marrow were confirmed. Thereafter, his lymph node swellings gradually regressed and his general condition improved. On day 22, he was discharged from hospital. Quantitative polymerase chain reaction for plasma EBV DNA on that day showed 1,700 copies/10^6 cells (normal range, <20). On day 24, a fluorodeoxyglucose-positron emission tomography/CT scan revealed CR. His sIL-2R level dropped to 622 IU/mL on day 47, then returned to a normal level (421 IU/mL) on day 68. In addition, a bone marrow examination was conducted on day 148. Flow cytometry showed no abnormal cells, the G-band showed a normal karyotype, immunoglobulin heavy chain (IgH) rearrangement was negative, and no evidence of disease was histologically evident. Thus, he achieved CR. So far, he is still in disease-free for more than 20 months.

**DISCUSSION**

We encountered a patient with RA who had been treated with immunosuppressant therapy, who developed composite lymphomas consisting of AITL and EBV-positive B-LPD. To date, only 3 cases have been reported that have exhibited metachronous or synchronous coexistence of AITL and B-LPD as OIIA-LPDs, comprising two metachronous cases and one synchronous case (9, 17). Concerning the synchronous case, Satou et al. presented a 72-year-old woman with RA who had received MTX (17). She was diagnosed with AITL through lymph node biopsy, and was found to be EBV-positive according to cutaneous lesion biopsy results. The disease did not exhibit spontaneous regression after MTX withdrawal; therefore, she was treated with a combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone and achieved CR. She remained alive 6 months after diagnosis without recurrence. Satou et al. also reported a 66-year-old woman with RA who had received MTX for 2.5 years as a metachronous case. Lymph node biopsy results were used to diagnose AITL and a CR was achieved post-MTX withdrawal. Thereafter, she relapsed and was found to
Composite lymphoma, a term introduced by Custer (21), is a rare pathological condition in which two different lymphomas co-exist simultaneously in one patient. Composite lymphoma has been reported to account for 1–4% of all lymphoma cases (22). Additionally, an analysis of 9,426 lymphoma cases in Japan revealed OIIA-LPD accounted for 147 (1.56%) cases (23). As previously stated, only 50 patients with MTX T-LPD have been reported. Composite lymphoma including T-cell lineage as an OIIA-LPD appears to be extremely rare and, as such, the clinicopathological features of MTX T-LPD remain to be elucidated. Clinicopathological feature of MTX T-LPD has yet to be elucidated because of its rarity. However, concerning our case, we consider EBV has key roles in lymphomagenesis.

In terms of EBV, Feng et al. suggested that MTX may directly reactivate latent EBV, as another cause of immunodeficiency, and have lymphadenopathy, and the lymph node biopsy results indicated diffuse large B-cell lymphoma (DLBCL). She died of the disease 93 months after initial diagnosis. Concerning a second metachronous case, Ishibuchi et al. presented a 66-year-old woman with polymyalgia rheumatica and a 4-month history of MTX therapy (9). An inguinal lymph node biopsy was performed and she was diagnosed withAITL. MTX therapy was stopped and the disease disappeared 6 months after MTX cessation. Eight months later, subcutaneous nodules appeared and a biopsy was performed, which later revealed DLBCL. With discontinuation of MTX only, the disease also regressed after 4 months. To our knowledge, no case ofAITL and B-LPD simultaneously occurring and both disappearing through withdrawal of immunosuppressant therapy only has previously been reported prior to our case.
lead to the development of LPDs in most MTX-associated LPDs (24). However, most proliferative T- and NK-cells are negative for EBV in MTX T-LPDs. Therefore, this suggestion does not appear readily applicable. As described in Table 1, while the tumor cells were positive for EBV in 8 (17%) of 48 patients, background cells were positive in 32 (82%) of 39 patients with available data (2, 4, 6–18). In relation to patients with AITL or those with AITL-like lymphomas, background cells were EBV-positive in 24 (96%) of 25 patients with available data. Therefore, immunodeficiency may suppress EBV-specific cytotoxic T-lymphocytes activity (25), and the reactivation of EBV suggests that the patients are immunodeficient and may suppress any immune response to prevent tumor growth. Furthermore, the relationship between EBV-positive background B-cells and AITL should be noted. AITL is a neoplasm due to clonal expansion of germinal center T-cells (26). Moreover, microarray studies have shown that tumor cells originate from follicular helper T-cells (27, 28). Of note, patients with AITL are frequently found to have EBV-positive B-cells in the microenvironment, as mentioned earlier. These B-cells accumulate somatic mutations through clonal expansion, and it has been suggested that some of these mutated cells develop B-cell lymphomas (29). Approximately 10% of patients with AITL have been found to have concurrent B-cell lymphoma at diagnosis or during the course of the disease (30, 31). In our case, B-LPD cells as well as CD20-positive cells surrounding AITL cells were EBER-positive. We speculate that MTX-associated EBV reactivation may have triggered the mutation and caused clonal expansion into the B-cells surrounding the AITL cells, leading to the development of B-LPD. Moreover, immunosuppressant can certainly accelerate lymphomageneses through inhibition of cytotoxic T-cell activity.

This case is the first to report AITL and EBV-positive B-LPD co-occurring as an OIIA-LPD that disappeared after we stopped immunosuppressant therapy only. AITL is known as a lymphoma that occasionally complicates B-LPD; thus, AITL co-locating with B-cell LPD as an OIIA-LPD might be overlooked. It is important to note that AITL can accompany B-LPD simultaneously or at a later stage, regardless of whether it is an OIIA-LPD.

**DATA AVAILABILITY STATEMENT**

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/supplementary material.

**AUTHOR CONTRIBUTIONS**

SK and KY wrote the manuscript, with support from all other authors. IT, JR, HA, HM, and NI treated the patient and provided the clinical history. YH and KK performed the histological examinations. All authors have critically revised and approved the final version of the manuscript.

**REFERENCES**

1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. WHO Classification of Tumours. Revised 4th ed. Lyon: IARC Press (2017).
2. Hoshida Y, Xu JX, Fujita S, Nakamichi I, Ikeda J, Tomita Y, et al. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. J Rheumatol. (2007) 34:322–31.
3. Ichikawa A, Arakawa F, Kiyasu I, Sato K, Miyoshi H, Niino D, et al. Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression. Eur J Haematol. (2013) 91:20–8. doi: 10.1111/ejh.12116
4. Mariette X, Cazals-Hatem D, Warszawski J, Liote F, Balandraud N, Sibilia J. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood. (2002) 99:3909–15. doi: 10.1182/blood.V99.11.3909
5. Yamakawa N, Fujimoto M, Kawabata D, Terao C, Nishikori M, Nakashima R, et al. A clinical, pathological, and genetic characterization of methotrexate-associated lymphoproliferative disorders. J Rheumatol. (2014) 41:293–9. doi: 10.3899/jrheum.120070
6. Claudino WM, Gibson B, Tse W, Krem M, Grewal J. Methotrexate-associated primary cutaneous CD30-positive cutaneous T-cell lymphoproliferative disorder: a case illustration and a brief review. Am J Blood Res. (2016) 6:1–5.
7. Hatachi S, Kunitomi A, Aozasa K, Yagita M. CD8+ T-cell lymphoproliferative disorder associated with Epstein-Barr virus in a patient with rheumatoid arthritis during methotrexate therapy. Mod Rheumatol. (2010) 20:500–5. doi: 10.3109/14397595.2010.500613
8. Homma H, Nakamura N, Kojima M, Ando K, Irie S, Bunno M, et al. Methotrexate-associated lymphoproliferative disorders mimicking angioimmunoblastic T-cell lymphoma. Pathol Res Pract. (2010) 206:9–13. doi: 10.1016/j.prp.2009.03.005
9. Ishibuchi H, Motegi S, Yamanaka M, Amano H, Ishikawa O. Methotrexate-associated lymphoproliferative disorder: sequential development of angioimmunoblastic T-cell lymphoma-like lymphoproliferation in the lymph nodes and diffuse large B-cell lymphoma in the skin in the same patient. Eur J Dermatol. (2015) 25:361–2. doi: 10.1684/edj.2015.2582
10. Koji H, Yazawa T, Nakabayashi K, Fujiyoka Y, Kamma H, Yamada A. CD8-positive T-cell lymphoproliferative disorder associated with Epstein-Barr virus-infected B-cells in a rheumatoid arthritis patient under methotrexate treatment. Mod Rheumatol. (2016) 26:271–5. doi: 10.3109/14397595.2013.850613
11. Kojima M, Itoh H, Hirabayashi K, Igarashi S, Tamaki Y, Murayama K, et al. Methotrexate-associated lymphoproliferative disorders. A clinicopathological study of 13 Japanese cases. Pathol Res Pract. (2006) 202:679–85. doi: 10.1016/j.prp.2006.05.007
12. Kondo S, Tanimoto K, Yamada K, Yoshimoto G, Suematsu E, Fujisaki T, et al. Mature T/NK-cell lymphoproliferative disease and Epstein-Barr virus infection are more frequent in patients with rheumatoid arthritis treated with methotrexate. Virchows Arch. (2013) 462:399–407. doi: 10.1007/s00428-013-1389-1
13. Miyazaki T, Fujimaki K, Shirasugi Y, Yoshiba F, Ohsaka M, Miyazaki K, et al. Remission of lymphoma after withdrawal of methotrexate in rheumatoid arthritis: relationship with type of latent Epstein-Barr virus infection. Am J Hematol. (2007) 82:1106–9. doi: 10.1002/ajh.21003
14. Nemoto Y, Taniguchi A, Kamioka M, Nakaoka Y, Hiroi M, Yokoyama A, et al. Epstein-Barr virus-infected subcutaneous panniculitis-like T-cell lymphoma associated with methotrexate treatment. Int J Hematol. (2010) 92:646–8. doi: 10.1007/s12185-010-0642-5
15. Sakaguchi R, Fujikawa K, Okamoto M, Matsuo E, Matsumoto K, Uchida T, et al. A case of rheumatoid arthritis complicated with nasal septum perforation...
due to methotrexate-associated lymphoproliferative disorder. Intern Med. (2019) 58:3167–71. doi: 10.2169/internalmedicine.2995-19
16. Saleh JZ, Lee LH, Schieke SM, Hosking PR, Hwang ST. Methotrexate-induced CD30(+)-T-cell lymphoproliferative disorder of the oral cavity. JAAD Case Rep. (2016) 2:354–6. doi: 10.1016/j.jcur.2016.02.002
17. Satou A, Tabata T, Miyoshi H, Kohno K, Suzuki Y, Yamashita D, et al. Methotrexate-associated lymphoproliferative disorders of T-cell phenotype: clinicopathological analysis of 28 cases. Mod Pathol. (2019) 32:1135–46. doi: 10.1038/s41379-019-0264-2
18. Takajo I, Umekita K, Ikei Y, Oshima K, Okayama A. Adult T-cell leukemia/lymphoma as a methotrexate-associated lymphoproliferative disorder in a patient with rheumatoid arthritis. Intern Med. (2018) 57:2071–5. doi: 10.2169/internalmedicine.0308-17
19. Marsee DK, Pinkus GS, Hornick JL. Podoplanin (D2-40) is a highly effective marker of follicular dendritic cells. Appl Immunohistochem Mol Morphol. (2009) 17:102–7. doi: 10.1097/PIM.0b013e318183a8e2
20. Xie Q, Chen L, Fu K, Harter J, Young KH, Sunkara J, et al. Podoplanin (d2-40): a new immunohistochemical marker for reactive follicular dendritic cells and follicular dendritic cell sarcomas. Int J Clin Exp Pathol. (2008) 1:276–84.
21. Custer R. Pitfalls on the diagnosis of lymphoma and leukemia from the pathologist's point of view. In: Second National Cancer Conference. New York, NY (1954).
22. Thirumala S, Esposito M, Fuchs A. An unusual variant of composite lymphoma: a short case report and review of the literature. Arch Pathol Lab Med. (2000) 124:1376–8.
23. Munro T, Miyoshi H, Sato K, Furuta T, Muta H, Kawamoto K, et al. Epidemiology and secular trends of malignant lymphoma in Japan: analysis of 9426 cases according to the World Health Organization classification. Cancer Med. (2018) 7:5843–58. doi: 10.1002/cam4.1805
24. Fung WH, Cohen JI, Fischer S, Li L, Sneller M, Goldbach-Mansky R, et al. Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas. J Natl Cancer Inst. (2004) 96:1691–702. doi: 10.1093/jnci/djh313
25. Landais E, Saulquin X, Houssaint E. The human T cell immune response to Epstein-Barr virus. Int J Dev Biol. (2005) 49:285–92. doi: 10.1387/ijdb.041947el
26. Attygalle A, Al-Jehani R, Duss TC, Munson P, Liu H, Du MQ, et al. Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10. Blood. (2002) 99:627–33. doi: 10.1182/blood.V99.2.627
27. Piccaluga PF, Agostinelli C, Califano A, Carbone A, Fantoni L, Ferrari S, et al. Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation. Cancer Res. (2007) 67:10703–10. doi: 10.1158/0008-5472.CAN-07-1708
28. de Leval L, Rickman DS, Thielen C, Reynies A, Huang YL, Delsol G, et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood. (2007) 109:4952–63. doi: 10.1182/blood-2006-10-055145
29. Brauninger A, Spieker T, Willenbrock K, Gaulard P, Wacker HH, Rajewsky K, et al. Survival and clonal expansion of mutating “forbidden” (immunoglobulin receptor-deficient) Epstein-Barr virus-infected B cells in angioimmunoblastic T cell lymphoma. J Exp Med. (2001) 194:927–40. doi: 10.1084/jem.194.7.927
30. Suefuji N, Niino D, Arakawa F, Karube K, Kimura Y, Kiyasu J, et al. Clinicopathological analysis of a composite lymphoma containing both T- and B-cell lymphomas. Pathol Int. (2007) 62:690–8. doi: 10.1111/j.1440-1827.2007.02858.x
31. Willenbrock K, Brauninger A, Hansmann ML. Frequent occurrence of B-cell lymphomas in angioimmunoblastic T-cell lymphoma and proliferation of Epstein-Barr virus-infected cells in early cases. Br J Haematol. (2007) 138:733–9. doi: 10.1111/j.1365-2141.2007.06725.x

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Kakiuchi, Yakushijin, Takagi, Rikitake, Akiyama, Matsuba, Hayashi, Kajimoto and Iwata. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.